Demircan Ozbalci
Overview
Explore the profile of Demircan Ozbalci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Determination of drug-related problems in the hematology service: a prospective interventional study
Albayrak A, Ozbalci D
BMC Cancer
. 2024 May;
24(1):552.
PMID: 38698336
Background: Patients with hematological malignancies often require multidrug therapy using a variety of antineoplastic agents and supportive care medications. This increases the risk of drug-related problems (DRPs). Determining DRPs in...
2.
Ozbalci D, Erdogan M, Alanoglu E, Sengul S, Yuceer K, Eroglu H, et al.
Leuk Res
. 2024 Feb;
138:107457.
PMID: 38382169
Introduction Background: This study evaluated the impact of adipose tissue indices on prognosis of HL. Methods: Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose...
3.
Sak R, Ozbalci D, Alanoglu E, Hekimler Ozturk K
Afr Health Sci
. 2024 Feb;
23(3):245-253.
PMID: 38357103
Background: Hypoxia is the hallmark of iron deficiency anemia (IDA) and in hypoxic environment, significant changes are observed in malignancy-related microRNAs (miRNA). Our aim is to examine whether there is...
4.
Ozbalci D, Alanoglu E, Findos E, Eroglu H
J Med Biochem
. 2023 Mar;
42(2):274-281.
PMID: 36987410
Background: Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV...
5.
Ozbalci D, Kumbul Doguc D, Yilmaz G, Ozturk O, Sirin F, Akcam F
Int J Lab Hematol
. 2021 Jun;
44(1):e13-e16.
PMID: 34191392
No abstract available.
6.
Ozbalci D
Med Hypotheses
. 2021 Jun;
152:110619.
PMID: 34102600
Sars Cov-2, the pathogen which belongs to the beta coronavirus family that is responsible for COVID-19, uses Angiotensin Converting Enzyme 2 (ACE2) as a receptor, which is responsible for controlling...
7.
Sahin M, Haznedaroglu I, Ozbalci D
Turk J Med Sci
. 2017 Jan;
46(6):1889-1893.
PMID: 28081344
Background/aim: FLT-3 ligand is a growth factor affecting the hematopoietic lineage. The aim of this study was to evaluate the variability of peripheral FLT-3 ligand during the clinical course of...
8.
Ozbalci D, Ergene U, Yazgan H
Turk J Haematol
. 2016 Jun;
28(3):239-40.
PMID: 27264376
No abstract available.
9.
Karacaoglu P, Asma S, Korur A, Solmaz S, Buyukkurt N, Gereklioglu C, et al.
Ann Hematol
. 2016 Apr;
95(6):993-1000.
PMID: 27068408
Sickle cell disease (SCD), one of the most common genetic disorders worldwide, is characterized by hemolytic anemia and tissue damage from the rigid red blood cells. Although hydroxyurea and transfusion...
10.
Ergene U, Akcali Z, Ozbalci D, Nese N, Senol S
Case Rep Infect Dis
. 2013 Mar;
2013:385190.
PMID: 23533852
Invasive aspergillosis is a major cause of morbidity and mortality in immunocompromised patients. Many cases of pulmonary, cutaneous, cerebral, and paranasal sinus aspergillosis in immunocompetent patient were defined in literature...